TriangleHEALTH PROFESSIONAL · SOURCE READING
Octreotide
Source: Childhood Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 12, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Childhood Thymoma / Treatment of Childhood Thymoma
Because thymoma shows high uptake of indium In 111–labeled octreotide, trials using this somatostatin analogue have been conducted in patients with refractory disease. In an Eastern Cooperative Oncology Group phase II trial of 42 patients, 4 patients had partial responses to octreotide alone, and 8 patients responded with the addition of prednisone to octreotide.[13]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice